• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 151

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

PT350 – Jim Gilligan – Psilocybin and Accessing the “Off” Switch...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY...

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic...

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction...

Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

GH Research Reports Second Quarter 2022 Financial Results and Provides Business...

PT349 – Brenna Gebauer – Slowing Down, The Ethics of Touch,...

1...150151152...303Page 151 of 303

EDITOR PICKS

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©